HOME > TOP STORIES

TOP STORIES

REGULATORY Kisunla to Follow Same Rules as Leqembi in Pricing and Post-Launch Review

October 10, 2024
BUSINESS Pfizer Curbs Supply of Avastin Biosimilar, 2 Others Hit by Knock-On Effect

October 9, 2024
BUSINESS Supply Curb Hits New Generic of Hirudoid Lotion, Demand Driven by Elective Care?

October 8, 2024
BUSINESS J&J Eyes Double-Digit Growth in Japan Pharma Biz from 2027, 50 Approvals by 2029

October 7, 2024
REGULATORY Panel OKs Withdrawal Rule for Conditional Nod, 2-Year Extension for Pediatric Data Protection towards PMD Act Amendment

October 4, 2024
ORGANIZATION Policy Veterans’ Group Proposes Special Drug Price Rule for Antibiotics

October 3, 2024
REGULATORY New Health Minister Eager to Build Pharma Ecosystem in Japan

October 3, 2024
REGULATORY New Finance Minister Vows Full Discussions with MHLW on FY2025 Revision

October 3, 2024
REGULATORY New Cabinet Might Move the Needle in Off-Year Debate: Industry Exec

October 2, 2024
REGULATORY Japan’s New PM Eyes Social Security Reform as Cabinet Unveiled

October 2, 2024
REGULATORY Takamaro Fukuoka Named as New Health Minister

October 1, 2024
REGULATORY Japan Compiles First Biosimilar Roadmap

October 1, 2024
ACADEMIA Pharmacies, Hospitals Scrambling to Address New LLP Coverage Rule, Concerns Swirl Around Misuse

October 1, 2024
REGULATORY Ishiba Elected as New LDP Leader, Hopes Are High for Medical and Pharma Policies

September 30, 2024
REGULATORY MHLW to Publish Info Necessary for Driving Biosimilar Switches in FY2025

September 27, 2024
REGULATORY Kisunla Subject to Prior Pricing Review as It Follows Leqembi’s Footsteps

September 26, 2024
REGULATORY Japan Approves Lilly’s Kisunla, Eisai’s ALS Med, Gilead’s Trodelvy, and Lots More

September 25, 2024
BUSINESS NHI-Market Price Gap on Narrowing Trend, but Results Remain Unpredictable

September 24, 2024
REGULATORY More Pregnant Cases Reported for COVID Meds, Panel Urges Greater Caution

September 24, 2024
BUSINESS Tsumura to Cover Return Costs for China Staff after Shenzhen Stabbing

September 24, 2024

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…